Loading...

QCLS Q/C TECHNOLOGIES INC Product Launches 8-K Filing

Q/C

QCLS

Q/C TECHNOLOGIES INC

(QCLS)

2023 8-K

Summary

Summary

Stock Grant Update

Capital Structure Update

Capital Structure Update

Acquisition Agreement

Private Placement Securities

Amendments to Bylaws

Nasdaq Compliance

Conference Call

Equity Incentive Plan

Stock Sale Agreement

Annual Meeting Notice

Capital Structure Change

Special Meeting Approval

Amendment to Certificate of...

Amendment to Correct Errors

Management Changes

Private Placements

Private Placements

Resignation of Officer

Material Modification to Ri...

Amendment to Certificate of...

Merger of Equals

Compliance Regained

Reverse Stock Split

Regulation FD Disclosure

Update on MYMD-1 Phase 2 Study

Compensation Committee Appr...

Regulation FD Disclosure

Annual Meeting Results

Annual Meeting Announcement

Press Release and Corporate...

Compensation Grant

Cancellation of Special Mee...

Announcement of Preclinical...

Joining LOT Network

Regulatory Status Announcement

Agreement for Stock and War...

Securities Purchase Agreement

Compensation Amendment

External Links:

MyMD Pharmaceuticals, Inc. announced plans for a Phase 2 clinical trial of oral MYMD-1 as a treatment for rheumatoid arthritis.

AI Assistant

Q/C TECHNOLOGIES INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.